Xoma garners $6M in antibody pact

Arana Therapeutics, a unit of Cephalon, has inked an antibody research deal with Xoma, which gets a $6 million fee and unspecified milestones. "We selected Xoma because of their ability to provide a complete suite of validated technologies that will further enable us to accelerate our antibody development programs toward the clinic," said Steffen Nock, acting chief executive officer of Arana. Arana release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.